Filter By Category
Archives
Share on -
AZETUKALNER
Generic Name: AZETUKALNER
ABSTRACT -
Azetukalner, also known as XEN1101 or encukalner, is an investigational small-molecule opener of KV7.2/KV7.3 potassium channels. It is being developed for focal-onset seizures, generalized seizure disorders, major depressive disorder, and related neurologic or psychiatric indications. It is not yet a routine approved antiseizure therapy. Molecular formula: C₂₃H₂₉FN₂O; molecular weight: 368.50 g/mol. Development/regulatory status: Investigational phase 3 development in neurologic and psychiatric indications.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- No approved routine dosing schedule is established.
- Clinical studies have evaluated once-daily oral capsule dosing under protocol-specific conditions.
- Dose selection depends on indication, tolerability, concomitant antiseizure medicines, psychiatric status, and trial criteria.
- Do not start, stop, or adjust without specialist supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Dizziness, somnolence, fatigue, or balance disturbance
- Headache, nausea, dry mouth, or gastrointestinal discomfort
- Blurred vision or cognitive slowing
- Mood changes, irritability, or psychiatric symptom changes
- Rash or hypersensitivity reactions
ALLERGIC REACTIONS -
Hypersensitivity to azetukalner or related compounds/products may occur. Symptoms may include:
- Infusion reaction or injection-site reaction where applicable
- Rash or urticaria
- Bronchospasm or breathing difficulty
- Facial, lip, tongue, or throat swelling
- Anaphylaxis
Important: Patients who develop an allergic reaction to azetukalner should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
- Other CNS depressants, alcohol, sedatives, and antiseizure medicines may increase dizziness or somnolence.
- Strong metabolic enzyme modifiers may alter exposure depending on final labeling.
- Psychiatric medicines require careful review in depression or bipolar studies.
- Patients should disclose all medicines, supplements, and recreational substances.
PREAUTIONS–
- Monitor seizure frequency, mood, suicidality, sedation, falls risk, and cognitive effects.
- Use caution in hepatic or renal impairment, pregnancy, lactation, and patients needing high-alert activities.
- Withdrawal or missed doses should be managed by a clinician to avoid seizure worsening.
WARNINGS –
- Antiseizure and CNS-active investigational drugs may affect mood, cognition, and seizure control.
- Seek urgent care for severe rash, suicidality, seizure cluster, or allergic reaction.
- Keep out of reach of children.
Share on -
. Developed by